1
项与 NK cell therapy (CellProtect Nordic Pharmaceuticals) 相关的临床试验An Open, Randomised, Controlled, Phase II Trial of CellProtect in Combination With Isatuximab Antibody Versus Isatuximab Antibody Alone as Maintenance Treatment in Patients With Multiple Myeloma Undergoing High Dose Treatment
Prospective, single center, randomized, open label, parallel group, 2-arm study assessing the clinical benefit in term of enhancement of overall response rate of Isatuximab in combination with CellProtect as compared to Isatuximab for the treatment of patients with newly diagnosed multiple myeloma who are eligible for stem cell transplantation (SCT) as maintenance after SCT.
100 项与 NK cell therapy (CellProtect Nordic Pharmaceuticals) 相关的临床结果
100 项与 NK cell therapy (CellProtect Nordic Pharmaceuticals) 相关的转化医学
100 项与 NK cell therapy (CellProtect Nordic Pharmaceuticals) 相关的专利(医药)
100 项与 NK cell therapy (CellProtect Nordic Pharmaceuticals) 相关的药物交易